Excelsior Biopharma Total Assets
Excelsior Biopharma total assets. Based on the latest financial reports, Excelsior Biopharma (6496) holds total assets worth NT$1.42 Billion TWD (≈ $44.67 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Excelsior Biopharma worth for the company's overall valuation and market capitalisation.
Total Assets of Excelsior Biopharma (2017–2025)
Total assets of Excelsior Biopharma from 2017 to 2025. This chart illustrates how Excelsior Biopharma's total assets have evolved over time, based on quarterly financial data. See 6496 share price today for real-time trading data and today's change.
Excelsior Biopharma - Asset Composition Analysis
Excelsior Biopharma Total Assets Breakdown (December 2025)
Excelsior Biopharma total assets breakdown as of December 2025. Excelsior Biopharma's total assets of NT$1.42 Billion consist of 48.9% current assets and 51.1% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 12.5% |
| Accounts Receivable | NT$231.30 Million | 15.6% |
| Inventory | NT$285.18 Million | 19.2% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Excelsior Biopharma's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 6496 working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Excelsior Biopharma's current assets represent 48.9% of total assets in 2025, a decrease from 88.3% in 2017.
- Cash Position: Cash and equivalents constituted 12.5% of total assets in 2025, down from 52.6% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is inventory at 19.2% of total assets.
Excelsior Biopharma Competitors by Total Assets
Key competitors of Excelsior Biopharma based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Sandoz Group AG
SW:SDZ
|
Switzerland | CHF22.86 Billion |
|
H Lundbeck A/S
CO:HLUN-B
|
Denmark | Dkr54.01 Billion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Viyash Scientific Limited
NSE:SEQUENT
|
India | Rs17.26 Billion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥5.11 Billion |
Excelsior Biopharma - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.55 | 3.40 | 5.29 |
| Quick Ratio | 0.82 | 1.82 | 4.45 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$247.12 Million | NT$449.99 Million | NT$1.33 Billion |
Excelsior Biopharma - Advanced Valuation Insights
This section examines the relationship between Excelsior Biopharma's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.66 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | -6.0% |
| Total Assets | NT$1.48 Billion |
| Market Capitalization | $33.97 Million USD |
Valuation Analysis
Below Book Valuation: The market values Excelsior Biopharma's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Excelsior Biopharma's assets decreased by 6.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Excelsior Biopharma (2017–2025)
The table below shows the annual total assets of Excelsior Biopharma from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | NT$1.48 Billion ≈ $46.75 Million |
-5.98% |
| 2024-12-31 | NT$1.58 Billion ≈ $49.73 Million |
+0.06% |
| 2023-12-31 | NT$1.58 Billion ≈ $49.69 Million |
-8.03% |
| 2022-12-31 | NT$1.71 Billion ≈ $54.03 Million |
-6.75% |
| 2021-12-31 | NT$1.84 Billion ≈ $57.94 Million |
-3.22% |
| 2020-12-31 | NT$1.90 Billion ≈ $59.87 Million |
+26.78% |
| 2019-12-31 | NT$1.50 Billion ≈ $47.22 Million |
-8.83% |
| 2018-12-31 | NT$1.64 Billion ≈ $51.80 Million |
-2.09% |
| 2017-12-31 | NT$1.68 Billion ≈ $52.90 Million |
-- |
About Excelsior Biopharma
Excelsior Biopharma Inc. develops and sells pharmaceutical products in Taiwan, China, and internationally. It offers general pharmaceuticals; orphan drugs; antidotes; rapid test kits and reagent; consumer products under the Repavar, Om3gafort, Oral7, and Excelsior Probiotics brand names; and over the counter drugs under the Norit, Puresenna, and Tazac brand names. The company also provides specia… Read more